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The increasing awareness of the ART regimens and program strategies that best prevent vertical transmission of HIV has led to a dramatic increase in access to ART among pregnant and breastfeeding women over the last decade. Global ART coverage is now estimated at 77% of pregnant women living with HIV, while ART coverage of all people living with HIV is lower, at approximately 53%. In 22 of the countries with the highest HIV burden-which together account for 90% of the global unmet PMTCT need-ART coverage has almost doubled for pregnant women, with 7 of these countries reaching 90% ART coverage rates among pregnant women living with HIV. 12 Moreover, motherto-infant transmission rates are now below 5% in several countries, including Ethiopia, South Africa, and Tanzania, moving toward the criteria for elimination of MTCT, defined in part by lowering new HIV cases to fewer than 50 per 100,000 live births. 9 These advances in PMTCT may signal to some that the mother-to-child transmission battle is won, or soon will be. This is unfortunately not the case. An estimated 90% of the new annual incident infections in children under 15 are still due to mother-to-child transmission, likely due to undiagnosed incident infection during the pregnancy or breastfeeding period, 13 and an estimated 2 million additional children under 15 will be living with HIV by 2020. 14 To eliminate new HIV infections among children by 2030, we will need to build upon the successes and investments that have carried us this far. Below, we outline 5 actionable strategies that will consolidate the gains earned by PMTCT programs and help avoid reversals in progress already made.
STRATEGIES TO PROTECT AND BUILD ON PMTCT GAINS Strategy #1: Advocate for Intensified Political and Financial Commitment for PMTCT
The key take-home message from this article is this: Providers, policy makers, programmers, and communities must continue to advocate strongly for PMTCT, a platform that cost effectively saves 2 lives simultaneously (mother and infant) while preventing HIV and promoting family health. After the much-needed initial scale up of funding for global PMTCT programming and achievements in the earlier years of this decade, both funding and progress have slowed. The year 2015 saw the first global decrease in PMTCT funding since 2010, and further cuts are planned. 15 As an example, PMTCT funding declined by 65% between 2013 and 2017 within the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). 16 While progress in antiretroviral (ARV) coverage for pregnant women showed rapid global scale up in the early part of the decade, increasing from the previous year by 17% in 2011 and by 13% in 2012, progress has slowed more recently, increasing by just 1.4% and 2.7% in 2016 and 2017, respectively. 9 Advocates for sustaining PMTCT funding must frequently remind policy makers that PMTCT is cost-effective and protects not just 1 but 2 lives. [17] [18] [19] Besides keeping mothers well, PMTCT protects HIV-exposed children from infection and decreases infant morbidity and mortality, thus reducing the need for infant ART and limiting HIV resistance. 20, 21 Leveraging the PMTCT platform to improve access to services to improve the health of mothers, infants, and children living with or at risk from HIV infection can help extend services efficiently in an era of increasingly limited resources. Family planning, nutrition, and maternal, neonatal, and child health services are often integrated, such as combining visits for immunizations with infant virological tests for HIV during the breastfeeding period. 22, 23 Other PMCT services can be integrated into immunization platforms, including rapid HIV testing of mothers who may have seroconverted during pregnancy, of those who did not come to antenatal care, or of those who did not receive an HIV test at antenatal care. Service integration is feasible across a variety of contexts, both in health facilities and in community settings, and can help protect recent hard-fought gains in child survival. 24, 25 With family planning, modeling exercises have shown that simple interventions such as the inclusion of contraceptives as part of the PMTCT package can have a greater impact on reducing the number of infants born with HIV infection than ARV drugs for PMTCT alone. 26, 27 Finally, PMTCT platforms can catalyze access to other HIV services, including HIV case finding for men and siblings through family-based models. Successful family-based interventions, such as "MTCT-Plus," enrolled family members into care and treatment in countries including Côte d'Ivoire, Kenya, Malawi, and Thailand. [28] [29] [30] [31] MTCT-Plus is a comprehensive approach, linking PMTCT programs with HIV-specific primary and preventive care for the whole family. 32 Conceptualized as a suite of services reaching entire families, the cost-effectiveness of PMTCT is compelling: Averting 90% of new pediatric infections alone would significantly reduce expenditures on pediatric care and treatment by country governments and donors. In addition to averting thousands of pediatric infections, a 90% decrease in PEPFAR's pediatric care and treatment costs could represent over $100 million in annual savings (based on PEPFAR planned expenditures in fiscal year 2017).
Strategy #2: Continue Focused Innovation to Target High-Risk Populations
PMTCT program innovation ushered in an era of "Treat All" and family-based care. Building on PMTCT programs that have redefined the HIV landscape, future innovations in PMTCT policy frameworks and program design must sensitively target populations that bear the highest burden of the epidemic, including adolescent girls and young women ages 10-24 and female sex workers.
Adolescent girls and young women. The "youth bulge" in Africa, where 61% of the population is under the age of 24, has made adolescent girls and young women a major at-risk population for HIV infection, 33 where they now account for nearly 75% of new HIV infections in sub-Saharan Africa. 34 Besides new incident infections, a substantial number of new HIV-positive diagnoses are made in perinatally infected adolescents. 35, 36 Together, these new and previously undiagnosed adolescent infections could represent a large contribution to new infant infections. Female sex workers. HIV prevalence is an estimated 13.5 times higher among female sex workers than the general female population. 37 The majority of female sex workers worldwide are mothers, and PMTCT platforms represent a unique opportunity to reach and retain these women and their infants in HIV care. [38] [39] [40] However, due to criminalization, stigma, discrimination, and violence, access to respectful antenatal and postnatal care remains elusive for them, and poor HIV-related outcomes for mothers who identify as female sex workers and their infants are sadly all too common. 39, [41] [42] [43] Programmers can use innovative approaches such as differentiated service delivery models that simplify and adapt HIV services to better meet the needs of people while reducing burdens on the health system 44 and stigma measurement tools for key populations 45 to inform the design of respectful, sensitive, and stigma-and discrimination-free services to ensure that pregnant and breastfeeding female sex workers are not marginalized from PMTCT programs. Since a substantial proportion of incident HIV infections will occur in high-risk women who are pregnant and breastfeeding, to truly eliminate mother-to-child transmission and to achieve the 90-90-90 HIV treatment goals (by 2020, 90% of all people living with HIV will know their HIV status, 90% of all those diagnosed with HIV will receive ART, and 90% of those on ART will have viral suppression), it will be critical to incorporate periodic HIV retesting and PMTCT programming into both adolescent-and female sex worker-friendly sexual and reproductive health services.
Strategy #3: Refine Novel Service Delivery Modalities for the PMTCT Context
Novel HIV service delivery approaches are crucial to reducing the burden on health facilities in the era of universal treatment, and programmers must advocate that pregnant and breastfeeding women living with HIV are included in these approaches. WHO recently outlined key considerations for promoting differentiated service delivery for pregnant and breastfeeding women living with HIV. 44 Under a differentiated service delivery model, people living with HIV who are clinically stable on treatment would need to make less frequent clinic visits than people who are ill and need intensive follow-up. As delivery models evolve to incorporate these considerations specifically for pregnant and breastfeeding women living with HIV, the package of PMTCT services should be deliberately developed to maximize the advantages of these models. Numerous studies have reported on the barriers for pregnant and breastfeeding women-including travel time, cost, and disclosure-that impact both access to and retention in care.
46-51 Many of these barriers are being addressed by bringing services closer to where women live. For example, in South Africa, almost 90,000 stable individuals belong to community ART groups implemented by Médecins Sans Frontières. 52 These groups have promoted adherence among stable patients with enhanced viral load suppression and higher CD4 T-cell counts, and they have also improved linkages to other supportive services and retention in care. 53, 54 Appointment spacing and fast-track drug refills have also saved costs and increased retention by reducing clinical visits, the amount of time spent at the clinic, and staff workloads. 55 Expanding the use of proven lay cadre platforms, such as mentor mothers and patient advocates, is another strategy to bring differentiated care models to pregnant and breastfeeding women. 25, 56, 57 During development of differentiated models of ART delivery, it will be crucial for programmers to address the distinct needs of women in the pregnancy and breastfeeding periods, and to consider integration with maternal, neonatal, and child health services, including child health visits. To ensure increased uptake and scale up of the recent WHO considerations for differentiated service delivery in PMTCT programs, programmers should seek out opportunities to innovate and to publicize any resulting successes.
Strategy #4: Recognize the Importance of Viral Load Monitoring During Pregnancy and Postpartum
Despite the promise held by new ARV formulations like dolutegravir for pregnant and breastfeeding women, current first-line ARV regimens have great potential to eliminate mother-to-child transmission as long as regular viral load monitoring is performed to identify challenges with ART adherence or clinical failure. The pregnancy and breastfeeding period represents a time-limited window in which reduced adherence and spikes in maternal viremia, even with ART usage, put the mother and infant at risk. 58 However, there has been inadequate attention to viral load monitoring in pregnancy and the postpartum period. Recent considerations suggest that the frequency of viral load testing should be increased during pregnancy and breastfeeding, with the goal of Recent WHO guidance for differentiated service delivery for pregnant or breastfeeding women highlights distinct considerations for clinically stable women who are accessing ART care at conception compared with women initiating ART during pregnancy or breastfeeding.
achieving suppression before delivery and maintaining suppression during breastfeeding. 59 Proposed interventions include viral load testing 4 weeks prior to delivery to set the stage for postpartum interventions in the event of high maternal viral load, including targeted birth testing and enhanced ARV birth prophylaxis. 59, 60 Much additional research remains on viral load monitoring in pregnancy and postpartum that cuts across clinical, programmatic, and behavioral areas. As a simple step, health cadres already in use in PMTCT programs, such as mentor mothers, can be employed to create demand for viral load monitoring; sensitize and inform mothers about the prolonged risk that incomplete adherence carries; and provide adherence support to mothers. For breastfeeding mothers, the clinical visits for the infant (including newborn visits, immunization visits, and well-child visits) can be leveraged as opportunities to provide access to maternal viral load testing throughout the period of infant exposure.
Strategy #5: Harness Technology to Advance PMTCT's Impact
Technological advances in monitoring and evaluation and HIV diagnostics have the potential to further drive PMTCT program success. The Global Plan brought significant improvements to measuring PMTCT program outcomes, including lowtech longitudinal registers to track mother-infant pairs and an updated monitoring framework as countries moved to providing lifelong ART for women under Option Bþ. 61, 62 Despite these advances, ongoing core challenges to monitoring and evaluation include tracking women who move between general ART and PMTCT programs, monitoring maternal viral suppression, and assessing final infant HIV status. The individual medical record data needed to accurately determine these PMTCT outcomes are challenging to track in settings where health infrastructure is limited and electronic systems are not available. 63 Several technologies have been used in PMTCT applications to complement paper-based systems to improve the collection and reporting of patient, facility, subnational, and national data to help programmers identify gaps in PMCT programming. Below are a few examples.
SMS-based reporting and messaging algorithms: Short message service (SMS) technology has been used widely for mobile health (mHealth) initiatives. Many of these initiatives, including MomConnect in South Africa, have been used to provide bidirectional information to pregnant mothers and to health facility staff. 64 Other SMS innovations in use for PMTCT include Uganda's nationwide weekly reporting system. 65 Each registered PMTCT site reports weekly on 9 indicators by using mobile phones to text data, including on ARV and test kit stock-outs. In 2015, an average of 79% of the 1,687 registered PMTCT sites reported their data, which is received in a central database. This "small data" is analyzed and shared via an electronic dashboard to stakeholders including program managers, district health officials, and implementing partners to allow decisions on targeted technical assistance to sites. The online dashboard program is available publicly at http://dashboard. mets.or.ug, and a smartphone app is also available (BþTrack). In Kenya, the HIV Infant Tracking System (HITSystem) uses algorithmbased computer and text messaging alerts. It was first demonstrated to improve the quality and efficiency of early infant diagnosis services in Kenyan hospitals and has been expanded to Malawi, Nigeria, and Tanzania. 66 The tool links key stakeholders-clinicians, laboratory staff, and mothers-through web-based and SMS notifications with the goal of improving mother-infant retention in care and health outcomes. Lessons from SMS technologies have demonstrated that for successful use in PMTCT programs, early and sustained engagement with stakeholders, including mothers, health staff, and policy makers, is critical to effectively impact PMTCT outcomes.
Laboratory dashboards: A key challenge in monitoring mother-infant health outcomes in PMTCT programs has been ineffectively used paper-based systems, which hamper the timely return of maternal viral load and infant virological test results, including early infant diagnosis. Lengthy turnaround times also contribute to delays in clinical management and represent a major challenge to managing viremia in mothers and infants living with HIV alike. suppression rates for pregnant and breastfeeding mothers; infant positivity rate; infant ART initiation rate; early infant diagnosis and viral load turnaround times; and district-and facility-level data disaggregation. Providers and program managers can monitor progress in real time at the site and lab levels using these dashboards to complement patient-level data, and make adjustments to laboratory or clinical processes to ensure that women with high viral load and HIV-exposed infants receive care in a timely manner.
Novel point-of-care instruments: One of the greatest challenges of the PMTCT cascade is the infant diagnostic test. In high-burden HIV settings, it can be very challenging to get samples from the patient to the laboratory and back, and then to communicate those results to the parent. 67 Point-of-care (POC) instruments have the potential to be used at birth or later for infant diagnosis per recent WHO guidelines. Though POC instruments require unique maintenance, reagents, and provider training, 68, 69 field evaluations have shown that POC instruments are feasible for use in infant diagnosis, [70] [71] [72] [73] where they increase infant retention in care. 74 When coupled with effective clinical and community linkage processes, POC infant testing promises to increase access to testing and improvements in retention among those diagnosed. 75 
CONCLUSION
PMTCT programs have made significant strides over the last 2 decades, but global funding for HIV is in decline while new pediatric infections persist. To continue to advance PMTCT programs, advocates, public health practitioners, and policy makers have promising options, including the ones outlined in this article. Strategies such as these will help ensure continued progress toward the elimination mother-to-child transmission of HIV, one of the key global health challenges of our time. 
